Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer

Anticancer Res. 2012 Mar;32(3):1103-6.

Abstract

Background: Docetaxel is a well tolerated chemotherapy for non-small cell lung cancer (NSCLC). However, few studies have investigated interstitial lung disease (ILD) associated with docetaxel. The purpose is to describe the incidence of this complication by using NSCLC patients.

Patients and methods: Between September 2002 and March 2008, 392 patients with advanced NSCLC were treated with docetaxel and we retrospectively reviewed the radiography. In total, 18 patients subsequently developed ILD associated with docetaxel.

Results: The incidence of ILD associated with docetaxel was 4.6%. In treated patients who showed an interstitial change on chest computed tomography (CT), the incidence was very high (25.9%). Chest radiograph showed diffuse and bilateral ground-glass appearance patterns.

Conclusion: Pre-existing interstitial change on CT was associated with a higher incidence of ILD (25.9%) among NSCLC patients treated with docetaxel. We don't recommend administering docetaxel for the patients with pre-existing interstitial change.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Docetaxel
  • Female
  • Humans
  • Lung Diseases, Interstitial / chemically induced*
  • Lung Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Taxoids / adverse effects*
  • Taxoids / therapeutic use

Substances

  • Antineoplastic Agents, Phytogenic
  • Taxoids
  • Docetaxel